Table 1 Subtypes of COAD in TCGA Cohort
From: Network-based identification of biomarkers for colon adenocarcinoma
Subtype | Description | Therapeutic implications |
|---|---|---|
c1 | Cell cycle dysregulation; p53 signaling pathway; loss of TCF7L2 and RPL18P1 | Cell cycle; p53; TCF7L2; RPL18P1 |
c2 | mTOR signing pathway and MAPK signaling pathway dysregulation | mTOR; MAPK |
c3 | Spliceosome; antigen processing and presentation; estrogen signaling pathway and mRNA surveillance pathway dysregulation; msi-h; high frequent OBSCN, MYCBP2, RYR2 and TTN mutations | Spliceosome; antigen processing and presentation; estrogen; NMD; msi-h; OBSCN; MYCBP2; RYR2; TTN |
c4 | Viral infections dysregulation; spliceosome | Antiviral drugs; spliceosome |
c5 | Rig-I-like receptor signaling pathway; FoxO signaling pathway; autophagy; insulin signaling pathway; focal adhesion | Rig-I-like receptor signaling pathway; FoxO signaling pathway; autophagy; insulin signaling pathway; focal adhesion |
c6 | Glycosaminoglycan biosynthesis-heparan sulfate; tight junction; circadian rhythm; ECM-receptor interaction; dysregulation; loss of ARHGEF28, BIN2P2 and SLC25A5P9 | Glycosaminoglycans; protein Claudin-2; circadian rhythm; ECM-receptor interaction; ARHGEF28; BIN2P2; SLC25A5P9 |